Equine IL-5 Antibody Summary
Leu20-Gly134
Accession # O02699
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data

Cell Proliferation Induced by IL‑5 and Neutralization by Equine IL‑5 Antibody. Recombinant Equine IL-5 (2470-EL) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Equine IL-5 (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Equine IL-5 Antigen Affinity-purified Poly-clonal Antibody (Catalog # AF2470). The ND50 is typically 0.500-6.00 µg/mL.

IL‑5 in Equine PBMCs. IL-5 was detected in immersion fixed equine peripheral blood mononuclear cells (PBMCs) treated with calcium ionomycin and PMA using Goat Anti-Equine IL-5 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2470) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-5
Interleukin-5 (IL-5) is a 40 kDa, secreted, heparin-binding, disulfide-linked homodimeric glycoprotein that belongs to the alpha -helical group of cytokines (1‑3). IL-5 is primarily produced by CD4+ Th2 cells, but other cell types such as eosinophils, endothelial cells, mast cells, visceral (airway) smooth muscle cells, bronchial epithelium, CD16+ NK cells and gamma δ T cells can also produce IL-5. Equine IL-5 is synthesized as a 134 amino acid (aa) precursor that contains a 19 aa signal sequence and a 115 aa mature segment. There are four alpha -helices, two potential N-linked glycosylation sites, and two cysteines that form interchain disulfide bonds with a second, antiparallel IL-5 molecule (3, 4). While human and mouse IL-5 have a potential NLS in their sequence, it is unclear if equine IL-5 has such a sequence. Mature horse IL-5 shares 71%, 89%, 88%, 83%, 66% and 63% aa sequence identity with mature human, bovine, feline, canine, mouse and rat IL-5, respectively.
The receptor for IL-5 consists of a 60 kDa ligand-binding subunit (IL‑5 R alpha ) and a 120 kDa signal-transducing subunit ( beta c). It is suggested that dimeric IL-5 binding to
IL‑5 R alpha recruits beta c, which subsequently covalently links with IL‑5 R alpha. This trimeric complex then associates with another trimeric complex to form the physiologic IL-5 receptor (6). Following binding, IL-5 has targeted effects. It promotes the maturation and migration of eosinophils, partially through the effects of eotaxin. It mobilizes eosinophils and CD34+ progenitors from marrow. It also enhances Ig release from B cells and contributes to IL-4 production. Finally, it primes basophils for histamine and leukotriene release (1, 2, 7).
- Lalani, T. et al. (1999) Ann. Allergy Asthma Immunol. 82:317.
- Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
- Zabeau, L. et al. (2003) Curr. Drug Targets Inflamm. Allergy 2:319.
- Vandergrifft, E.V. and D.W. Horohov (1998) GenBank Accession # O02699.
- Geijsen, N. et al. (2001) Cytokine Growth Factor Rev. 12:19.
- Bagley, C.J. et al. (1997) Blood 89:1471.
- Mattes, J. and P.S. Foster (2003) Curr. Drug Targets Inflamm. Allergy 2:169.
Product Datasheets
Citation for Equine IL-5 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Treating insect-bite hypersensitivity in horses with active vaccination against IL-5
Authors: A Fettelscho, V Fettelscho, F Thoms, C Giese, M Daniel, F Olomski, J Kamarachev, K Birkmann, M Bühler, M Kummer, A Zeltins, E Marti, TM Kündig, MF Bachmann
J. Allergy Clin. Immunol., 2018-04-04;0(0):.
Species: Equine
Sample Types: Recombinant Protein
Applications: ELISA Detection
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Equine IL-5 Antibody
There are currently no reviews for this product. Be the first to review Equine IL-5 Antibody and earn rewards!
Have you used Equine IL-5 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image